Modular Medical Regains Nasdaq Compliance

Insulin delivery company meets minimum bid price requirement after recent stock price drop.

Apr. 16, 2026 at 7:07pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a polished metal insulin pump component, a glass syringe, and medical documents, conceptually representing the precision and innovation of Modular Medical's insulin delivery technology.Modular Medical's next-generation insulin delivery technology aims to raise the standard of diabetes care.San Diego Today

Modular Medical, Inc., a development-stage medical device company focused on innovative insulin delivery technology, announced that it has regained compliance with the Nasdaq Capital Market's minimum bid price continued listing requirement. The company's stock price had previously fallen below the $1.00 minimum, but has now maintained a closing price above that threshold for the required 10 consecutive trading days.

Why it matters

Maintaining Nasdaq listing compliance is critical for Modular Medical as it works to commercialize its next-generation insulin delivery products. Losing Nasdaq listing could have significantly impacted the company's access to capital markets and ability to attract investors.

The details

Modular Medical received a letter from Nasdaq notifying the company that as of April 14, 2026, its common stock had closed above the $1.00 minimum bid price for the last 10 consecutive trading days, regaining compliance with Nasdaq Marketplace Rule 5550(a)(2). This resolves the prior non-compliance issue the company had faced.

  • Modular Medical received the Nasdaq compliance letter on April 16, 2026.
  • The company's stock price closed above $1.00 for 10 straight trading days as of April 14, 2026.

The players

Modular Medical, Inc.

A development-stage medical device company focused on innovative insulin delivery technology.

Nasdaq Stock Market LLC

The stock exchange that lists Modular Medical's shares and sets compliance requirements for listed companies.

Paul DiPerna

The founder of Modular Medical and a seasoned medical device professional who previously founded Tandem Diabetes.

Got photos? Submit your photos here. ›

The takeaway

Modular Medical's ability to regain Nasdaq compliance demonstrates the company's resilience and commitment to meeting regulatory requirements as it continues developing its innovative insulin delivery technology. This milestone positions the company to maintain access to capital markets and investor interest as it works toward product commercialization.